Pulmonary fibrosis: Nerandomilast inhibits phosphodiesterase 4B, may treat multiple forms of disease
A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials. Pulmonary fibrosis is a very serious disease, with a life prognosis of 3 to 5 years after ...
May 21, 2025
0
3